Korea is set to begin domestic production of actinium-225 (Ac-225), a key raw material for next-generation cancer treatments, as early as the first half of 2025. With production facilities already in ...

Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML) patients needing a bone marrow transplant in the US, buoyed by top-line data from a pivotal trial ...

NEW YORK (AP) — NEW YORK (AP) — Actinium Pharmaceuticals Inc. (ATNM) on Thursday reported a loss of $11.6 million in its third quarter. On a per-share basis, the New York-based company said it ...

Actinium Pharmaceuticals ( (ATNM)) has released its Q3 earnings. Here is a breakdown of the information Actinium Pharmaceuticals presented to its investors. Actinium Pharmaceuticals, Inc. is a ...

Actinium Pharma has revealed the data from its SIERRA trial of radioligand therapy Iomab-B for acute myeloid leukaemia (AML) patients needing a bone marrow transplant, bolstering the case for the ...

(RTTNews) - Actinium Pharmaceuticals Inc. (ATNM) Monday announced a narrower loss for the third quarter. The September quarter loss was $11.6 million, compared to $13.3 million a year ago.

Bill Gates' nuclear power venture, TerraPower Isotopes, has become the first to boost production of a radioactive substance that has shown new promise in the fight against cancer, called actinium ...

Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable precision radiopharmaceuticals for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or ...